CollPlant Biotechnologies (CLGN) EBITDA Margin (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly EBITDA Margin came in at 4267.12% in Q1 2026, down 418693.0% YoY from N/an in Q1 2025, and up 18.72% on a QoQ basis from 5250.0% in Q4 2025.
CollPlant Biotechnologies (CLGN) EBITDA Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of EBITDA Margin data on file, last reported at 4267.12% in Q1 2026.
- Quarterly EBITDA Margin fell 418693.0% year-over-year to 4267.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1695.12% (down 146219.0% YoY) and the FY2025 annual result came in at 484.31%, up 286540.0% from the prior year.
- EBITDA Margin grew to 4267.12% in Q1 2026, from 5250.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 4417.35% in Q1 2024 to a low of 113550.0% in Q3 2024.
- A 5-year average of 8843.21% and a median of 2059.08% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 11354999 bps — and 2025, when it jumped 10899545 bps.
- Tracing CLGN's EBITDA Margin over 5 years: stood at 8062.07% in 2022, then surged by 79 bps to 1694.98% in 2023, then slumped by 43 bps to 2423.17% in 2024, then plunged by 117 bps to 5250.0% in 2025, then grew by 19 bps to 4267.12% in 2026.
- The last three EBITDA Margin figures came in at 4267.12% (Q1 2026), 5250.0% (Q4 2025), and 4554.55% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | -4,267.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -4,267.12% |
| Dec 31, 2025 | -5,250.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 30, 2025 | -80.19% |
| Dec 31, 2024 | -2,423.17% |
| Sep 30, 2024 | -113,550.00% |
| Jun 30, 2024 | 1,769.48% |
| Mar 31, 2024 | 4,417.35% |
| Dec 31, 2023 | -1,694.98% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | 55.74% |
| Mar 31, 2023 | 812.70% |
| Dec 31, 2022 | -8,062.07% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -1,227.10% |
| Sep 30, 2021 | -2,210.00% |
| Jun 30, 2021 | -443.27% |
| Mar 31, 2021 | 69.14% |